AstraZeneca PLC (AZN)vsRani Therapeutics Holdings Inc (RANI)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
RANI
Rani Therapeutics Holdings Inc
$0.84
+2.51%
HEALTHCARE · Cap: $121.59M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1258174% more annual revenue ($61.37B vs $4.88M). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
RANI
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+83.8%
Fair Value
$7.70
Current Price
$0.84
$6.86 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 893.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : RANI
The strongest argument for RANI centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 893.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while RANI is a hypergrowth play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.71 — expect wider price swings.
RANI is growing revenue faster at 893.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 31/100), backed by strong 17.0% margins. RANI offers better value entry with a 83.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology, which enables the oral administration of biologic therapeutics. This groundbreaking approach not only enhances patient adherence but also aligns with the growing preference for non-invasive treatment options. With a robust and diversified pipeline targeting multiple therapeutic areas, Rani Therapeutics is strategically positioned for significant growth. The company’s commitment to cutting-edge research and development, along with key partnerships, further underscores its potential to make impactful advancements in the pharmaceutical sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?